PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Results 1 - 20 of 128 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar Orthonormal (92.68) Submitted: 3/12/2014 10:32:22 AM : Outperform Start Price: $8.19 PDLI Score: +2.27

Magic Formula pick 3/21/2012
renewed 3/12/2014

Recs

0
Member Avatar NorbertV (< 20) Submitted: 1/28/2014 5:12:41 PM : Outperform Start Price: $8.81 PDLI Score: -10.16

2 years 33% gain plus excellent dividend. P/E at 5 right now no reason it shouldn't continue up.

Recs

0
Member Avatar TheValueDude (60.57) Submitted: 1/9/2014 5:27:33 PM : Outperform Start Price: $8.50 PDLI Score: -3.06

Screen: Under $10B, Top 10% EBIT/EV, Z Score >1.81

Recs

0
Member Avatar lnlrmtg (27.06) Submitted: 1/8/2014 2:31:12 AM : Outperform Start Price: $8.54 PDLI Score: -3.80

fundamentals

Recs

0
Member Avatar veredia2 (66.02) Submitted: 1/8/2014 1:43:11 AM : Outperform Start Price: $8.54 PDLI Score: -3.80

Low P/E, return on assets is excellent. looks like a stock at a bargain price. Solid management

Recs

0
Member Avatar zzlangerhans (99.74) Submitted: 1/6/2014 11:59:28 AM : Outperform Start Price: $8.52 PDLI Score: -4.16

I haven't done the math here, but PDL has a competent and experienced management team that seems to have made a calculated decision to keep the company going with new royalty transactions rather than shutting it down as the Queen patents expired. The share price has been grinding upward except for a weird obelisk that formed after a positive reaction to the last earnings PR followed by a gap down on a negative SA article. Does the SA bear have a point? No clue. They put the article behind a paywall and I'll never give the manipulators and censors behind that website a dime.

Another risk of green thumbing PDL is that CAPS won't credit me with the 0.15 quarterly dividend, so I'll place my starting price of approximately 8.71 in the text which should be lowered by 0.15 every three months with ex-dividend if the site is being maintained correctly.

Recs

0
Member Avatar Haugurafpeningum (88.85) Submitted: 1/5/2014 2:24:06 PM : Outperform Start Price: $8.52 PDLI Score: -3.56

porte and zz 1

Recs

0
Member Avatar Stregachess (< 20) Submitted: 10/3/2013 12:07:46 AM : Underperform Start Price: $7.70 PDLI Score: +1.99

Analyst love this stock but the IP can't be controlled they are in for a rough ride. Without patent protection it's all just a dream.

Recs

0
Member Avatar SpartanMAC (21.08) Submitted: 8/28/2013 9:42:49 PM : Outperform Start Price: $7.58 PDLI Score: -3.77

Top 30, 275M minimum market cap.

Recs

0
Member Avatar tgainesphd (59.54) Submitted: 4/18/2013 8:01:13 PM : Outperform Start Price: $6.99 PDLI Score: -1.06

Good growth potential.

Recs

0
Member Avatar Aquinas31 (40.59) Submitted: 4/3/2013 4:56:19 PM : Outperform Start Price: $6.84 PDLI Score: +2.30

Dividends going up, probably hits 8+ by 4th quarter

Recs

0
Member Avatar dunloggin (77.07) Submitted: 2/5/2013 1:45:05 PM : Outperform Start Price: $6.20 PDLI Score: +11.47

Dividend paying stock.

Recs

0
Member Avatar bIlluminati (30.14) Submitted: 1/23/2013 10:50:58 AM : Underperform Start Price: $6.31 PDLI Score: -7.42

Patent usage running out. Six more quarters of earnings. Should be trading for cash plus 4-6x current quarter's earnings.

Recs

1
Member Avatar pavlos1971 (99.68) Submitted: 1/2/2013 3:58:59 PM : Underperform Start Price: $5.54 PDLI Score: -10.44

Short in RL@7.31

Recs

0
Member Avatar pdhaag (75.92) Submitted: 10/15/2012 9:18:41 PM : Underperform Start Price: $7.31 PDLI Score: +14.62

Most of it's patents are set to expire between 2014 and 2017, at which point revenue will drop dramatically. It's only a matter of time.

Recs

0
Member Avatar EnigmaDude (97.98) Submitted: 10/8/2012 11:29:41 PM : Outperform Start Price: $7.23 PDLI Score: -12.66

biotech trading for a P/E of 6 with a 7% dividend!

Recs

1
Member Avatar FoxForce5contest (25.40) Submitted: 8/18/2012 9:18:30 PM : Outperform Start Price: $6.47 PDLI Score: -2.23

on 8-18-12 Momentum21 picked PDLI

Recs

0
Member Avatar myfairshare (< 20) Submitted: 8/17/2012 6:04:53 PM : Outperform Start Price: $6.47 PDLI Score: -2.23

I think the royalties are the best position to be in, for the pharmaceutical plays.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $5.92 PDLI Score: +5.00

Biotech with solid pipeline

Recs

0
Member Avatar DaveKATL (44.58) Submitted: 5/4/2012 9:05:19 PM : Outperform Start Price: $5.40 PDLI Score: +21.43

Strictly a momentum play. They have no drugs in the pipeline and it doesn't look like they're planning anymore - it's like their just burning this company bright and getting what they can out of it.

Featured Broker Partners


Advertisement